Attitudes Toward the Global Allocation of Chinese COVID-19 Vaccines: Cross-sectional Online Survey of Adults Living in China.
COVID-19
COVID-19 vaccines
China
cross-sectional
epidemiology
global allocation
health policy
pandemic
public attitudes
public health
survey
vaccines
Journal
JMIR public health and surveillance
ISSN: 2369-2960
Titre abrégé: JMIR Public Health Surveill
Pays: Canada
ID NLM: 101669345
Informations de publication
Date de publication:
07 06 2022
07 06 2022
Historique:
received:
10
09
2021
accepted:
26
04
2022
revised:
22
02
2022
pubmed:
29
4
2022
medline:
10
6
2022
entrez:
28
4
2022
Statut:
epublish
Résumé
COVID-19 vaccines are in short supply worldwide. China was among the first countries to pledge supplies of the COVID-19 vaccine as a global public product, and to date, the country has provided more than 600 million vaccines to more than 200 countries and regions with low COVID-19 vaccination rates. Understanding the public's attitude in China toward the global distribution of COVID-19 vaccines could inform global and national decisions, policies, and debates. The aim of this study was to determine the attitudes of adults living in China regarding the global allocation of COVID-19 vaccines developed in China and how these attitudes vary across provinces and by sociodemographic characteristics. We conducted a cross-sectional online survey among adults registered with the survey company KuRunData. The survey asked participants 31 questions about their attitudes regarding the global allocation of COVID-19 vaccines developed in China. We disaggregated responses by province and sociodemographic characteristics. All analyses used survey sampling weights. A total of 10,000 participants completed the questionnaire. Participants generally favored providing COVID-19 vaccines to foreign countries before fulfilling domestic needs (75.6%, 95% CI 74.6%-76.5%). Women (3778/4921, 76.8%; odds ratio 1.18, 95% CI 1.07-1.32; P=.002) and those living in rural areas (3123/4065, 76.8%; odds ratio 1.13, 95% CI 1.01-1.27; P=.03) were especially likely to hold this opinion. Most respondents preferred providing financial support through international platforms rather than directly offering support to individual countries (72.1%, 95% CI 71%-73.1%), while for vaccine products they preferred direct provision to relevant countries instead of via a delivery platform such as COVAX (77.3%, 95% CI 76.3%-78.2%). Among our survey sample, we found that adults are generally supportive of the international distribution of COVID-19 vaccines, which may encourage policy makers to support and implement the distribution of COVID-19 vaccines developed in China worldwide. Conducting similar surveys in other countries could help align policy makers' actions on COVID-19 vaccine distribution with the preferences of their constituencies.
Sections du résumé
BACKGROUND
COVID-19 vaccines are in short supply worldwide. China was among the first countries to pledge supplies of the COVID-19 vaccine as a global public product, and to date, the country has provided more than 600 million vaccines to more than 200 countries and regions with low COVID-19 vaccination rates. Understanding the public's attitude in China toward the global distribution of COVID-19 vaccines could inform global and national decisions, policies, and debates.
OBJECTIVE
The aim of this study was to determine the attitudes of adults living in China regarding the global allocation of COVID-19 vaccines developed in China and how these attitudes vary across provinces and by sociodemographic characteristics.
METHODS
We conducted a cross-sectional online survey among adults registered with the survey company KuRunData. The survey asked participants 31 questions about their attitudes regarding the global allocation of COVID-19 vaccines developed in China. We disaggregated responses by province and sociodemographic characteristics. All analyses used survey sampling weights.
RESULTS
A total of 10,000 participants completed the questionnaire. Participants generally favored providing COVID-19 vaccines to foreign countries before fulfilling domestic needs (75.6%, 95% CI 74.6%-76.5%). Women (3778/4921, 76.8%; odds ratio 1.18, 95% CI 1.07-1.32; P=.002) and those living in rural areas (3123/4065, 76.8%; odds ratio 1.13, 95% CI 1.01-1.27; P=.03) were especially likely to hold this opinion. Most respondents preferred providing financial support through international platforms rather than directly offering support to individual countries (72.1%, 95% CI 71%-73.1%), while for vaccine products they preferred direct provision to relevant countries instead of via a delivery platform such as COVAX (77.3%, 95% CI 76.3%-78.2%).
CONCLUSIONS
Among our survey sample, we found that adults are generally supportive of the international distribution of COVID-19 vaccines, which may encourage policy makers to support and implement the distribution of COVID-19 vaccines developed in China worldwide. Conducting similar surveys in other countries could help align policy makers' actions on COVID-19 vaccine distribution with the preferences of their constituencies.
Identifiants
pubmed: 35483084
pii: v8i6e33484
doi: 10.2196/33484
pmc: PMC9177168
doi:
Substances chimiques
COVID-19 Vaccines
0
Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e33484Informations de copyright
©Hanzhi Yu, Runming Du, Minmin Wang, Fengyun Yu, Juntao Yang, Lirui Jiao, Zhuoran Wang, Haitao Liu, Peixin Wu, Till Bärnighausen, Lan Xue, Chen Wang, Shannon McMahon, Pascal Geldsetzer, Simiao Chen. Originally published in JMIR Public Health and Surveillance (https://publichealth.jmir.org), 07.06.2022.
Références
Sci Rep. 2021 Apr 27;11(1):9042
pubmed: 33907202
Lancet. 2020 Jun 20;395(10241):1883
pubmed: 32563355
J Med Internet Res. 2021 Apr 29;23(4):e26940
pubmed: 33844637
Engineering (Beijing). 2020 Oct;6(10):1108-1114
pubmed: 32983582
Glob Public Health. 2021 Aug-Sep;16(8-9):1512-1521
pubmed: 33764847
Lancet. 2020 Apr 18;395(10232):1305-1314
pubmed: 32247320
Vaccines (Basel). 2021 Feb 25;9(3):
pubmed: 33668695
J Travel Med. 2021 Feb 23;28(2):
pubmed: 33274387
Lancet. 2020 Jul 4;396(10243):63-70
pubmed: 32505220
Lancet. 2020 Jun 13;395(10240):1845-1854
pubmed: 32450106
Nat Hum Behav. 2022 Feb;6(2):207-216
pubmed: 35102361
BMJ Glob Health. 2021 Feb;6(2):
pubmed: 33589419
ERJ Open Res. 2020 Nov 02;6(4):
pubmed: 33263060
J Travel Med. 2021 Jun 1;28(4):
pubmed: 33635318
BMC Public Health. 2021 Oct 13;21(1):1851
pubmed: 34645399
Vaccines (Basel). 2021 Feb 25;9(3):
pubmed: 33668923
Lancet. 2020 Dec 5;396(10265):1789
pubmed: 33278922
Hum Vaccin Immunother. 2021 Jul 3;17(7):2279-2288
pubmed: 33522405
Lancet. 2020 Mar 7;395(10226):764-766
pubmed: 32105609
Lancet. 2020 Aug 15;396(10249):479-488
pubmed: 32702299
JAMA Netw Open. 2020 Sep 1;3(9):e2023020
pubmed: 32990736
Lancet. 2021 Mar 13;397(10278):1023-1034
pubmed: 33587887